This appeal arose from a challenge to the Madhya Pradesh High Court’s orders which had declined to outrightly quash the blacklisting and debarment orders passed against the appellant-firm (a licensed drug manufacturer and supplier). The appellant’s products (Ascorbic Acid and Ethambutol Hydrochloride tablets supplied to government hospitals) were declared “Not of Standard Quality” (NSQ) based on initial laboratory reports, prompting authorities to blacklist the firm for three years and debar products for two years without following the mandatory second-sample re-testing procedure stipulated in the tender document.
The Supreme Court allowed the appeal and quashed the blacklisting and debarment orders. The Court held that the authorities committed a fundamental procedural flaw by ignoring Clause 6 of Annexure IX of the tender, which mandates sending a second sample to another laboratory for confirmation before blacklisting can occur. Furthermore, because the drug batches had long expired and the High Court’s re-testing directions were rendered impossible by efflux of time, the foundational reports could no longer be legally sustained against the appellant.
- Factual Background:
- The appellant-firm supplied drugs to government hospitals in Madhya Pradesh under a valid tender. Following adverse quality reports declaring four batches as “Not of Standard Quality” (NSQ), the authorities issued a show-cause notice and hastily passed orders on September 30, 2024, blacklisting the firm for three years and debarring a product for two years.
- Violation of Mandatory Tender Procedure (Clause 6):
- Clause 6 of Annexure IX to the Tender Document explicitly mandates that if a sample fails a quality test, a second sample from the same batch must be drawn and sent to another laboratory, and blacklisting can only follow upon confirmation by the second laboratory.
- The respondents admitted that this mandatory procedure was bypassed before issuing the blacklisting and recovery orders.
- Loss of Opportunity for Re-Testing and Efflux of Time:
- Although the High Court directed re-testing at the Central Government Laboratory, authorities failed to comply within the stipulated 15 days, and the drug batches subsequently expired.
- Citing established jurisprudence (Medipol Pharmaceutical India Pvt. Ltd. v. PGI), the Supreme Court reiterated that when state authorities cause delays that deprive a supplier of the valuable right to have a sample retested by a superior laboratory before its shelf life expires, any penal action based on the initial report becomes void.
- Final Outcome:
- The Supreme Court set aside the High Court’s orders and quashed the original blacklisting and debarment orders dated September 30, 2024, and October 1, 2024, due to incurable procedural infirmities and the irretrievable loss of the re-testing opportunity.
2026 INSC 1143
M/s Jpee Drugs v. State of Madhya Pradesh and Others (D.O.J. 06.10.2026)




